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Objectives The aim of this study was to evaluate long-term clinical outcomes after implantation of sirolimus-eluting stents (SES)
or paclitaxel-eluting stents (PES) among patients with unprotected left main coronary artery (LMCA) disease.
Background There have been few comparisons of long-term outcomes among currently available drug-eluting stents (DES) for
the treatment of LMCA disease.
Methods A total of 858 consecutive patients with unprotected LMCA stenosis were treated with SES (n  669) or PES
(n  189) between May 2003 and June 2006. Primary outcome was the composite of death, myocardial infarc-
tion (MI), or target vessel revascularization (TVR).
Results Baseline clinical and angiographic characteristics were similar in the 2 groups. During 3 years of follow-up, the
adjusted risk of primary composite outcome was similar among the groups (SES vs. PES: 25.8% vs. 25.7%, haz-
ard ratio [HR]: 0.95, 95% confidence interval [CI]: 0.64 to 1.41, p  0.79). The 2 groups also showed a compa-
rable adjusted rate of each component of outcome: death (9.1% vs. 11.0%, HR: 0.92, 95% CI: 0.47 to 1.80, p 
0.82), MI (8.1% vs. 8.0%, HR: 0.80, 95% CI: 0.43 to 1.48, p  0.47), and TVR (12.1% vs. 10.6%, HR: 1.10, 95%
CI: 0.53 to 2.29, p  0.81). The 3-year rates of definite or probable stent thrombosis were 0.6% in the SES
group and 1.6% in the PES group (adjusted p  0.18).
Conclusions In consecutive patients with unprotected LMCA disease undergoing DES implantation, SES and PES showed
similar long-term clinical outcomes in terms of death, MI, repeat revascularization, and stent thrombosis.
(J Am Coll Cardiol 2009;54:853–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.071c
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oypass surgery has been recommended—on the basis of
linical studies comparing coronary artery bypass grafting
CABG) with medical therapy—as the treatment of choice
or patients with unprotected left main coronary artery
LMCA) disease, and recent appropriateness criteria for
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ccepted April 6, 2009.oronary revascularization regard CABG as the most ap-
ropriate treatment for LMCA disease (1–3). However,
ecent improvements in interventional techniques and ad-
unctive pharmacology have led to a reevaluation of the role
f percutaneous coronary intervention (PCI) as a viable
reatment option for LMCA disease (4–8). In addition,
nterest in left main stenting has intensified with the
vailability of drug-eluting stents (DES), which have been
ound to significantly reduce the rates of restenosis and repeat
evascularization (9–16), as compared with bare-metal stents.
owever, few data are available on the long-term clinical
utcomes of currently available DES for treatment of unpro-
ected LMCA disease. Therefore, we compared the 3-year
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SES Versus PES in Left Main Disease August 25, 2009:853–9clinical outcomes after implanta-
tion of sirolimus-eluting stents
(SES) and paclitaxel-eluting stents
(PES) in patients with unpro-
tected LMCA disease.
Methods
Study population and proce-
dures. As previously described
(8), the MAIN-COMPARE
(Revascularization for Unpro-
tected Left Main Coronary Ar-
tery Stenosis: Comparison of
Percutaneous Coronary Angio-
plasty versus Surgical Revascu-
larization) registry holds data on
consecutive patients from 12 ma-
or academic cardiac centers in Korea that performed PCI or
ABG for unprotected LMCA disease (defined as stenosis
50%) between January 2000 and June 2006. The registry
s initiated and sponsored by the Korean Society of Inter-
entional Cardiology, and there was no industry involve-
ent in the design, conduct, or analysis of this study.
urrent study population comprised 858 consecutive pa-
ients with unprotected LMCA disease who underwent
ES implantation between May 2003 and June 2006.
Stent implantation methods for left main disease have
een described previously (4,10,17). The choice of SES
Cypher and Cypher Select, Cordis, Johnson & Johnson,
ew Brunswick, New Jersey) or PES (Taxus Express and
iberté, Boston Scientific, Natick, Massachusetts) was at
he discretion of the physician. Interventions for any other
linically important types of coronary artery disease were
erformed according to current practice guidelines (2). All
atients undergoing PCI were prescribed aspirin plus clo-
idogrel (loading dose, 300 or 600 mg) before or during the
oronary intervention. After the procedure, aspirin was
ontinued indefinitely, and clopidogrel was continued for at
east 6 months. Extended use of clopidogrel beyond 6
onths was at the discretion of the physician.
This study was approved by the ethics committee at each
ospital, which allowed the use of clinical data for this
tudy.
tudy end points and definitions. The primary outcome
as the composite of death, myocardial infarction (MI), and
arget vessel revascularization (TVR) during follow-up.
econdary outcomes were each clinical outcome (death, MI,
r TVR) and stent thrombosis.
All-cause mortality was considered. An MI was defined
s a pathologic new Q wave on an electrocardiogram or an
ncrease in creatine kinase-myocardial band level to 3
imes the upper limit of the normal range. In our study,
VR was defined as repeat revascularization of the treated
essel, including any segments of the left anterior descend-
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
DES  drug-eluting stent(s)
LMCA  left main coronary
artery
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TVR  target vessel
revascularizationng and/or left circumflex artery (15). Stent thrombosis was 0ssessed by Academic Research Consortium definitions,
ith the pre-specified key end point being definite or
robable (18). By the timing of presentation, stent throm-
osis was classified as acute, subacute, late, and very late if it
ccurred within 24 h, 30 days, 30 days to 1 year, or 1
ear, respectively, after the procedure. Procedural success
as defined as a residual diameter stenosis of 30% by
uantitative coronary angiography, without in-hospital ma-
or adverse events (death, Q-wave MI, stent thrombosis, or
mergent revascularization).
All outcomes of interest were confirmed by documenta-
ion at each hospital and were centrally adjudicated by an
ndependent group of clinicians who were blinded to stent
ype.
ata collection and follow-up. Clinical, angiographic,
rocedural or operative, and outcome data were collected
ith the use of a dedicated Internet-based reporting system.
or validation of complete follow-up data, information
bout vital status was obtained through July 15, 2007, from
he National Population Registry of the Korea National
tatistical Office with a unique personal identification num-
er. Follow-up MI, stent thrombosis, and TVR were based
n clinical diagnoses assigned by the patient’s physician and
ere centrally adjudicated by the local events committee at
he University of Ulsan College of Medicine, Asan Medical
enter, Seoul, Korea.
tatistical analysis. Continuous variables were compared
ith the Student t test or the Wilcoxon rank sum test, and
ategorical variables were compared with the chi-square test
r Fisher exact test as appropriate. Unadjusted cumulative
vent rates were estimated by the Kaplan-Meier method
nd compared with the log-rank test.
Crude and adjusted risk for adverse outcomes were com-
ared by univariate and multivariable Cox proportional hazards
egression analysis (19). Variables reported in Tables 1 and 2
ith a p value 0.2 in univariate analyses were candidates for
ultivariable Cox proportional hazards models. The final
odels were determined by backward elimination procedure.
he proportional hazards assumption was confirmed by exam-
nation of log (log [survival]) curves and by testing of partial
Schoenfeld) residuals (20), and no relevant violations were
ound.
A propensity score analysis was also performed to control
election biases among the DES groups (21). The propen-
ity scores were estimated without regard to outcome
ariables, with multiple logistic regression analysis that
ncluded all covariates listed in Tables 1 and 2. Model
iscrimination was assessed with c-statistics (0.79), and
odel calibration was assessed with Hosmer-Lemeshow
tatistics (p  0.38). The individual propensity score as well
s type of stent were incorporated into Cox proportional
azard regression models as a covariate to calculate the
ropensity adjusted hazard ratio.
All p values were 2-sided, and a probability value of p .05 was considered significant. All statistical analyses were
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August 25, 2009:853–9 SES Versus PES in Left Main Diseaseerformed with SPSS version 12.0 for Windows (SPSS
nc., Chicago, Illinois).
esults
aseline characteristics and procedure. Of the 858 pa-
ients with unprotected LMCA disease who underwent
ES implantation, 669 patients (78%) were treated with
ES and 189 patients (22%) were treated with PES. The
aseline clinical, angiographic, and procedural character-
stics of these 2 groups are listed in Tables 1 and 2. There
ere no significant between-group differences in clinical
haracteristics, except that patients treated with PES
ere older and had higher mean EuroScore than those
reated with SES. The 2 groups also had comparable
ngiographic and procedural characteristics, except that a
igher percentage of patients with SES underwent the
rocedure with intravascular ultrasound guidance and
irect stenting.
n-hospital and long-term clinical outcomes. During the
Baseline Clinical Characteristicsof Patients According to Stent GroupTable 1 Baseline Clinical Characteristicsof Patients According to Stent Grou
Variable
Demographic characteristics
Age (yrs) 6
Male sex
Coexisting conditions or other risk factors
Diabetes
Any type
Insulin-treated
Hypertension
Hyperlipidemia
Current smoker
Family history of CAD
Previous myocardial infarction
Previous coronary angioplasty
Previous congestive heart failure
Cerebrovascular disease
Peripheral vascular disease
Chronic lung disease
Renal failure
Atrial fibrillation
Clinical indications for index procedure
Silent ischemia
Stable angina
Unstable angina
Acute myocardial infarction
Ejection fraction (%)
Median
Interquartile range
EuroScore
Mean EuroScore
EuroScore 6 (high-risk score)
Data are mean  SD or n (%).
CAD  coronary artery disease; PES  paclitaxel-eluting stent(s); Sndex hospital stay, there were 21 (2.4%) in-hospital deaths s2.4% in the SES, and 2.6% in the PES group), 4 (0.5%)
-wave MIs (0.4% in the SES, and 0.5% in the PES
roup), and 4 (0.5%) urgent revascularizations (0.3% in the
ES, and 1.1% in the PES group). The rate of procedural
uccess was similar in the SES (97.4%) and PES (98.1%)
roups (p  0.37).
The median follow-up was 852 days (interquartile
ange 605 to 1,118 days) in the overall population, 875
ays (interquartile range 635 to 1,143 days) in the SES
roup, and 876 days (interquartile range 627 to 1,143
ays) in the PES group. Complete follow-up data for
ajor clinical events were obtained in 98.9% of the
verall cohort. During the entire follow-up period, 65
atients (8.6%) died, 42 (64.6%) from a cardiovascular
ause; 66 (7.7%) had an MI (5 Q-wave, 61 non–Q-
ave), and 92 (10.7%) had TVR. Table 3 summarizes the
umulative incidences and long-term relative risks of
linical outcomes during the 3-year follow-up among the
groups. A crude analysis showed that the risks of death,
I, TVR, and the primary composite outcome were
69)
PES
(n  189) p Value
11.2 64.9  10.8 0.002
2.2) 133 (70.4) 0.62
1.5) 65 (34.4) 0.46
.8) 18 (9.5) 0.44
1.7) 101 (53.4) 0.68
9.4) 52 (27.5) 0.61
6.0) 49 (25.9) 0.98
.6) 12 (6.3) 0.91
.8) 18 (9.5) 0.44
9.7) 34 (18.0) 0.59
.1) 4 (2.1) 0.46
.8) 12 (6.3) 0.28
.9) 4 (2.1) 0.88
.7) 3 (1.6) 0.14
.0) 9 (4.8) 0.66
.5) 3 (1.6) 0.44
0.07
.3) 4 (2.1)
3.0) 45 (23.8)
6.0) 101 (53.4)
7.6) 39 (20.6)
0.51
60
7 54–67
2.8 4.6  2.5 0.02
6.5) 60 (31.7) 0.15
rolimus-eluting stent(s).p
SES
(n  6
2.1 
483 (7
211 (3
52 (7
346 (5
197 (2
174 (2
44 (6
52 (7
132 (1
21 (3
59 (8
13 (1
25 (3
27 (4
17 (2
22 (3
221 (3
308 (4
118 (1
61
55–6
4.1 
177 (2imilar in the SES and PES groups (Fig. 1, Table 3).
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SES Versus PES in Left Main Disease August 25, 2009:853–9hese results were also consistent after multivariable and
ropensity-adjusted Cox regression analyses.
During the follow-up period, 7 patients (0.8%) had
efinite or probable stent thrombosis: 4 (0.6%) in the SES,
nd 3 (1.6%) in the PES group (adjusted p  0.18). Of the
atients treated with SES, 1 had acute stent thrombosis and
rude and Adjusted Hazard Ratios of Clinical Outcomes AccordingTable 3 Crude and Adjusted Hazard Ratios of Clinical Outcome
Outcome
Rates (%) at
3 Yrs* Crude
Outcome SES PES Hazard Ratio (95% CI) p
Primary composite outcomes
Death, MI, or TVR 25.8 25.7 1.02 (0.71–1.49)
Secondary outcome
Death 9.1 11.0 0.88 (0.49–1.56)
MI 8.1 8.0 0.95 (0.54–1.70)
TVR 12.1 10.6 1.04 (0.63–1.73)
Angiographic and ProceduralCharacteristics of ati nts According to Stent GroTable 2 Angiog phic and ProceduralCharacteristics of Patients According
Variable
Lesion location
Ostium and shaft
Bifurcation
Extent of diseased vessel
Left main only
Left main plus single-vessel disease
Left main plus 2-vessel disease
Left main plus 3-vessel disease
Right coronary artery disease
Restenotic lesion
Use of glycoprotein IIb/IIIa inhibitors
Guidance of intravascular ultrasound
Direct stenting
Lesion preparation
Cutting balloon
Directional atherectomy
Rotational atherectomy
Maximal inflation pressure (mm Hg)
Number of stents implanted in LMCA lesion
Total stent length (mm) in LMCA lesion
Average stent diameter (mm)
Number of stents implanted/patients (including LMCA
and other vessels)
Total stent length/patients (including LMCA and other vesse
Bifurcation treatment
Single stenting (cross over)
Complex stenting (2 stents)
Kissing stenting
T stenting
Crush stenting
Others
Data are mean  SD or n (%).
LMCA  left main coronary artery; other abbreviations as in Table 1Outcome rates were derived from Kaplan-Meier curves. †Hazard ratio for SES with reference of PES.
CI  confidence interval; MI  myocardial infarction; TVR  target vessel revascularization; other abbrhad subacute stent thrombosis (2, 5, and 11 days after the
rocedure). Of those treated with PES, 2 patients had
ubacute stent thrombosis (3 and 22 days after the proce-
ure) and 1 had late stent thrombosis (201 days after the
rocedure). Two patients died of stent thrombosis (case-
atality rate, 28.6%).
ent Groupording to Stent Group
Multivariable Adjusted Adjusted for Propensity
Hazard Ratio† (95% CI) p Value Hazard Ratio (95% CI) p Value
0.95 (0.64–1.41) 0.79 0.99 (0.67–1.46) 0.95
0.92 (0.47–1.80) 0.82 0.93 (0.50–1.71) 0.81
0.80 (0.43–1.48) 0.47 0.87 (0.48–1.59) 0.66
1.10 (0.53–2.29) 0.81 1.11 (0.55–2.26) 0.77
tent Group
SES
(n  669)
PES
(n  189) p Value
0.08
277 (41.4) 92 (48.7)
392 (58.6) 97 (51.3)
0.19
125 (18.7) 29 (15.3)
164 (24.5) 36 (19.0)
178 (26.6) 58 (30.7)
202 (30.2) 66 (34.9)
280 (41.9) 89 (47.1) 0.20
19 (2.8) 8 (4.2) 0.33
51 (7.6) 8 (4.2) 0.10
495 (76.4) 123 (65.8) 0.004
154 (23.0) 25 (13.2) 0.003
25 (3.7) 4 (2.1) 0.28
18 (2.7) 3 (1.6) 0.39
2 (0.3) 0 0.45
15.8  3.9 15.8  4.4 0.99
1.2  0.5 1.2  0.5 0.70
33.4  22.1 31.5  20.6 0.28
3.3  0.2 3.4  0.2 0.04
2.1  1.2 2.1  1.2 0.96
58.5  23.2 55.1  21.3 0.26
0.94
244 (62.2) 60 (61.9)
148 (37.8) 37 (38.1) 0.90
48 (32.4) 10 (27.0)
26 (17.6) 8 (21.6)
71 (48.0) 18 (48.6)
3 (2.0) 1 (2.7)to Sts Acc
Value
0.90
0.66
0.87
0.87up
to S
ls)eviations as in Table 1.
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August 25, 2009:853–9 SES Versus PES in Left Main Diseaseiscussion
ajor findings in the current study were that: 1) PCI with
ES implantation was effective and safe in patients with
nprotected LMCA disease; 2) no significant differences in
ong-term cardiovascular events were observed between SES
nd PES; and 3) the documented stent thrombosis rate after
MCA stenting with both stent types was low.
Current guidelines have recommended CABG as the
reatment of choice for patients with unprotected LMCA
isease (1,2), on the basis of clinical trials demonstrating
urvival benefit of CABG over medical treatment (22–
5). However, because of technical feasibility and marked
dvancements in PCI devices and adjunctive pharmacol-
gy, many clinicians have performed PCI as an alterna-
ive revascularization option for these patients. Several
egistry trials (9 –11,13,14,26) have also reported encour-
ging results—that elective DES implantation in patients
ith LMCA disease shows acceptable mid-term out-
omes, with mortality rates of 0% to approximately 5%
nd need for TLR rates of 5% to approximately 14%
uring 1 year. These studies had several limitations,
owever, including relatively low patient numbers, lim-
ted duration of follow-up, and use of a single-center
egistry.
Several small observational studies have compared
Figure 1 Kaplan-Meier Curves of the Primary Composite End Po
MI  myocardial infarction; PES  paclitaxel-eluting stent(s); SES  sirolimus-elututcomes of the 2 first-generation types of DES (SES vs. sES) for LMCA stenting (12,27,28). In a single-center,
onrandomized study comparing SES and PES in 110
atients with LMCA disease, angiographic results (late
oss in the main branch [0.32 vs. 0.46 mm] and side
ranch [0.36 vs. 0.52 mm]) and long-term clinical
utcomes (death/MI [16% vs. 18%] and TVR [9% vs.
1%]) were comparable (28). A recent large randomized
rial (ISAR-LEFT MAIN [Intracoronary Stenting and
ngiographic Results: Drug-Eluting Stents for Unpro-
ected Coronary Left Main Lesions]) found that SES and
ES were equally effective and safe in patients undergo-
ng unprotected LMCA stenting (29). After 12 months,
he incidences of death (6.6% vs. 5.0%), MI (4.6% vs.
.0%), stroke (1.0% vs. 1.7%), and major adverse cardiac
vent (death, MI, or revascularization; 15.8% vs. 13.6%)
ere similar in the SES and PES groups, as were
ngiographic restenosis rates at 6 to 9 months (19.4% vs.
6.0%) and 2-year revascularization rates (7.8% vs. 6.5%).
ur results validate the findings from the recent RCT
ISAR-LEFT MAIN). In addition, our study provides
he longer-term follow-up results up to median 3 years in
routine clinical practice.
Most clinical studies comparing SES and PES for
on-LMCA coronary lesions have reported better angio-
raphic results with SES than with PES due to higher
Death, MI, TVR) and Each Component Between SES abd PES
nt(s); TVR  target vessel revascularization.int (
ing steuppression of neointimal growth by the former. This
a
s
p
l
p
l
o
t
t
o
c
s
p
t
u
o
0
r
E
d
1
(
p
i
p
t
a
m
l
S
o
c
p
t
s
i
t
a
a
t
s
o
d
n
f
fi
C
I
d
s
t
t
L
R
D
i
d
a
R
1
1
1
1
858 Lee et al. JACC Vol. 54, No. 9, 2009
SES Versus PES in Left Main Disease August 25, 2009:853–9ngiographic trend, however, was not directly reflected in
ignificant differences in clinical outcomes (30,31). In
atients with LMCA stenting, the impact of late lumen
oss on clinical outcomes such as TVR might be less
ronounced, due to the relatively short length of the
esions and the larger artery diameter, as compared with
ther coronary lesions.
Concerns have been raised recently regarding the long-
erm safety of DES, with particular regard to late stent
hrombosis and late mortality (32–34). Increasing concern
ver stent thrombosis, which might have more catastrophic
onsequences in patients undergoing unprotected LMCA
tenting, and a lack of long-term clinical data have ham-
ered the widespread use of PCI with DES as an alternative
o CABG. A recent multicenter registry of 731 patients
ndergoing LMCA stenting with DES found that the rate
f definite or probable thrombosis after 30 months was
.95% (35). Similar results were observed in another large
egistry (DELFT study [Sirolimus Versus Paclitaxel Drug-
luting Stent for Left Main Registry]), with 3-year rates of
efinite, probable, and possible stent thrombosis of 0.6%,
.1%, and 4.4%, respectively (27,36), and in a clinical study
ISAR-LEFT MAIN) with a 2-year rate of definite or
robable stent thrombosis of 1.3%. We observed a similar
ncidence of definite or probable stent thrombosis (0.8%),
roviding further evidence that DES implantation in pa-
ients with unprotected LMCA disease results in lower or,
t worst, similar rates of stent thrombosis and long-term
ortality than are observed in patients with other coronary
esions (37).
tudy limitations. First, our study was a nonrandomized
bservational study. Second, because the choice of spe-
ific DES type was mainly determined according to the
hysician’s or patients’ preference, there might be selec-
ion bias. Despite multivariable adjustment with propen-
ity score, hidden biases might exist because of the
nfluence of unmeasured hidden confounders. In addi-
ion, because we did not perform a detailed angiographic
nalysis, we could not exclude the possibility of concealed
ngiographic superiority for a specific type of DES. Due
o the exploratory nature of the current study, a priori
ample size calculation was not pre-specified. Therefore,
ur results could be underpowered to detect significant
ifferences. Finally, because we did not study whether
ewer-generation stents are as effective or more effective
or LMCA lesions, the current findings apply only to the
rst-generation DES platform, such as PES and SES.
onclusions
n a large cohort of patients with unprotected LMCA
isease who underwent DES implantation, SES and PES
howed similar long-term clinical outcomes.
Randomized trials with long-term follow-up are required
o clarify the long-term efficacy and safety of DES implan-ation compared with CABG for treatment of unprotected
MCA disease.
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